Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to higher improvement in WHO functional class compared with placebo (high certainty).
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with ERA (moderate certainty).
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).
Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i probably leads to higher improvement in WHO functional class compared with placebo (moderate certainty).
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo (low certainty).
Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i may leads to higher improvement in WHO functional class compared with placebo (low certainty).
Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i probably leads to lower improvement in WHO functional class compared with placebo (moderate certainty).
Prostacyclin probably leads to higher improvement in WHO functional class compared with control (moderate certainty).
Selexipag showed no clear difference in improvement in WHO functional class compared with placebo (moderate certainty).
The intervention showed no clear difference in improvement in WHO Functional Class (low certainty).
The findings closest to your search, judged one by one by TypeSafe's Jev model.